<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlSource>
  <Section SecID="560" OrdBy="10" Name="General">
    <Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Diagnosis and management of type 2 diabetes mellitus (T2DM) in adults: percentage of patients ages 18 to 75 years old with T2DM with poorly controlled glucose or any of the specified cardiovascular risk factors.&lt;/div&gt;" />
    </Field>
    <Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Redmon B, Caccamo D, Flavin P, Michels R, O'Connor P, Roberts J, Smith S, Sperl-Hillen J. Diagnosis and management of type 2 diabetes mellitus in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2014 Jul. 85 p.  [197 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
  </Section>
  <Section SecID="563" OrdBy="40" Name="Measure Domain">
    <Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one">
      <FieldValue Value="Clinical Quality Measures: Outcome" />
    </Field>
    <Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one">
      <FieldValue Value="Clinical Quality Measure:  Process" />
    </Field>
  </Section>
  <Section SecID="566" OrdBy="70" Name="Brief Abstract">
    <Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is used to assess the percentage of patients ages 18 to 75 years old with type 2 diabetes mellitus (T2DM) with any of the following:&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;1&quot;&gt;&#xA;    &lt;li&gt;Glycated hemoglobin (HgbA1c) greater than 9% &lt;/li&gt;&#xA;    &lt;li&gt;Atherosclerotic cardiovascular disease (ASCVD) and not on a statin &lt;/li&gt;&#xA;    &lt;li&gt;Established ASCVD and no documentation of daily aspirin use (unless contraindicated) &lt;/li&gt;&#xA;    &lt;li&gt;Blood pressure measurement greater than 160/100 mmHg &lt;/li&gt;&#xA;    &lt;li&gt;Currently smoke &lt;/li&gt;&#xA;    &lt;li&gt;Any of the above &lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;p&gt;This measure represents the composite rate. See the &quot;Basis for Disaggregation&quot; field for details.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The priority aim addressed by this measure is to decrease the percentage of adult patients ages 18 to 75 with type 2 diabetes mellitus (T2DM) with poorly controlled glucose and cardiovascular risk factors. &lt;/p&gt;&#xA;&lt;p&gt;Due to the high percentage of the United States (U.S.) population that is diagnosed with diabetes and the effect diabetes has on other comorbidities, appropriate management will improve the patient's experience of care and the health of the population, reducing office visits, emergency department visits, and cardiovascular complications. Other related conditions will in turn reduce the total cost of care.&lt;/p&gt;&#xA;&lt;p&gt;Appropriate medication management targeting glycemic control, hypertension, and lipid management is important for reducing morbidity and mortality, and improving long-term quality of life for patients diagnosed with T2DM. Lifestyle changes such as nutrition therapy, weight loss, increased exercise, and appropriate education and self-management strategies are pivotal to improved outcomes. Inadequate access to care for chronic disease management as well as the cost of medication can contribute to poor control of T2DM and associated cardiovascular risk factors.&lt;/p&gt;&#xA;&lt;p&gt;For most chronic diseases, including diabetes, the most efficient improvement strategy is to focus on a limited number of specific improvement goals. These may be based on observed gaps in care, potential clinical impact, cost considerations or other criteria (O'Connor, 2005). In T2DM, focusing on glycemic control, lipid control and blood pressure control is a strategy that has been shown to be effective in preventing up to 53% of heart attacks and strokes, the leading drivers of excess mortality and costs in adults with diabetes (Gaede et al., 2003).&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12556541&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;O'Connor PJ. Commentary--improving diabetes care by combating clinical inertia. Health Serv Res. 2005 Dec;40(6 Pt 1):1854-61. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16336552&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Redmon B, Caccamo D, Flavin P, Michels R, O'Connor P, Roberts J, Smith S, Sperl-Hillen J. Diagnosis and management of type 2 diabetes mellitus in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2014 Jul. 85 p.  [197 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Type 2 diabetes mellitus (T2DM); atherosclerotic cardiovascular disease (ASCVD); glycated hemoglobin (HgbA1c); blood pressure; low-density lipoprotein (LDL); statin therapy; tobacco use; aspirin use &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Number of patients ages 18 to 75 years old with type 2 diabetes mellitus (T2DM) (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Number of patients with any of the following:&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;1&quot;&gt;&#xA;    &lt;li&gt;Glycated hemoglobin (HgbA1c) greater than 9% &lt;/li&gt;&#xA;    &lt;li&gt;Atherosclerotic cardiovascular disease (ASCVD) and not on a statin &lt;/li&gt;&#xA;    &lt;li&gt;Established ASCVD and no documentation of daily aspirin use (unless contraindicated) &lt;/li&gt;&#xA;    &lt;li&gt;Blood pressure measurement greater than 160/100 mmHg &lt;/li&gt;&#xA;    &lt;li&gt;Currently smoke &lt;/li&gt;&#xA;&lt;/ol&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure">
    <Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice">
      <FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" />
    </Field>
    <Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diabetes is a chronic disease that afflicts approximately 26.9% of United States (U.S.) residents aged 65 years and older. 1.9 million are diagnosed with diabetes every year, and an additional 7.0 million go undiagnosed and untreated (Centers for Disease Control and Prevention [CDC], 2011). More than 1 in 5 health care dollars in the U.S. goes to the care of people with diagnosed diabetes, costing $245 billion dollars annually. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The benefits of a multifactorial approach to diabetes care are supported by the results of the Steno 2 Study of 160 patients with type 2 diabetes mellitus (T2DM) and microalbuminuria. Multifactorial interventions achieved a 50% reduction in mortality and significant reduction in microvascular complications five years after ending a 7.8-year multifactorial intervention that achieved glycated hemoglobin (A1c) of 7.8%, low-density lipoprotein (LDL) 83 mg/dL, blood pressure (BP) 131/73, compared to a conventional group that achieved A1c 9%, LDL 126 mg/dL and BP 146/78 (Gaede et al., 2008). Results of this study are consistent with the need for reasonable blood glucose control with emphasis on blood pressure and lipid management. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalized patients with diabetes suffer increased morbidity, mortality, length of stay, and other related hospital costs compared to non-hyperglycemic inpatients (Umpierrez et al., 2002). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperglycemia has been associated with increased infection rates and poorer short-term and long-term outcomes in critically ill patients in the intensive care unit, post-myocardial infarction, and post-surgical settings (van den Berghe et al., 2001). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is a substantial increase in the prevalence of depression among people with diabetes as compared to the general adult population (Anderson et al., 2001). Depression impacts the ability of a person with diabetes to achieve blood glucose control, which in turn impacts the rate of development of diabetes complications (de Groot et al., 2001; Lustman &amp;amp; Gavard, 2001). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sleep apnea is a prevalent condition in obese patients with type 2 diabetes and is associated with significant comorbidities including hypertension, cardiovascular disease and insulin resistance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Up to 21% of patients with T2DM are found to have retinopathy at the time of diagnosis of diabetes mellitus (Fong et al., 2004). Generally retinopathy progresses from mild background abnormalities to preproliferative retinopathy to proliferative retinopathy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Achieving near-normal glycemic control lowers risk of diabetes microvascular complications such as retinopathy, nephropathy and amputations. Achieving A1c of 6.9 to 7.9% may also significantly reduce macrovascular complications based on Steno-2 and UK Prospective Diabetes Study (UKPDS) data (Hemmingsen et al., 2013; Callaghan et al., 2012; Anderson et al., 2011; Action to Control Cardiovascular Risk in Diabetes Study Group et al., 2008; ACCORD Study Group et al., 2010; Ismail-Beigi et al., 2010; Duckworth et al., 2009; NICE-SUGAR Study Investigators et al., 2009; Ray et al., 2009; Turnbull et al., 2009; Abraira et al., 2009; ADVANCE Collaborative Group et al., 2008; Gaede et al., 2008; Holman et al., 2008). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tobacco smoking increases risk of macrovascular complications 4% to 400% in adults with T2DM and also increases risk of macrovascular complications. Tobacco cessation is very likely to be the single most beneficial intervention that is available, and it should be emphasized by clinicians. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Uncontrolled hypertension is a major cardiovascular risk factor that also accelerates the progression of diabetic nephropathy (Morrish et al., 1991). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seventy to seventy-five percent of adult patients with diabetes die of macrovascular disease, specifically coronary, carotid and/or peripheral vascular disease. In most patients with diabetes, use of a statin can reduce major vascular events. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="3502" OrdBy="170" ID="576" Name="Evidence for Additional Information Supporting Need for the Measure" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Abraira C, Duckworth WC, Moritz T, VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. 2009 Feb;11(2):150-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18671796&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15;363(3):233-44. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20587587&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18539917&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18539916&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 Jun;24(6):1069-78. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11375373&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, Simmons DL, Sperl-Hillen JA, Bigger T, Cuddihy R, O'Conner PJ, Sood A, Zhang P, Sullivan MD, Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care. 2011 Apr;34(4):807-12. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21346183&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22696371&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Centers for Disease Control and Prevention (CDC). National diabetes fact sheet, 2011: fast facts on diabetes. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2011. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001 Jul-Aug;63(4):619-30. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11485116&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19092145&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R. Retinopathy in diabetes. Diabetes Care. 2004 Jan;27(Suppl 1):S84-7. [10 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14693935&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 Feb 7;358(6):580-91. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18256393&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;11:CD008143. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24214280&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1565-76.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I, ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 Aug 7;376(9739):419-30. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20594588&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lustman PJ, Gavard JA. Psychosocial aspects of diabetes in adult populations. In: National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995. p. 507-18.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Morrish NJ, Stevens LK, Fuller JH, Jarrett RJ, Keen H. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia. 1991 Aug;34(8):590-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1936663&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19318384&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009 May 23;373(9677):1765-72. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19465231&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Redmon B, Caccamo D, Flavin P, Michels R, O'Connor P, Roberts J, Smith S, Sperl-Hillen J. Diagnosis and management of type 2 diabetes mellitus in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2014 Jul. 85 p.  [197 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M, Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 Nov;52(11):2288-98. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19655124&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002 Mar;87(3):978-82. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11889147&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11794168&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="37" OrdBy="200" ID="579" Name="National Guideline Clearinghouse Link" Type="xref">
      <FieldValue Value="&lt;a href=&quot;http://www.guideline.gov/content.aspx?id=48544&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of type 2 diabetes mellitus in adults.&lt;/a&gt;" />
    </Field>
  </Section>
  <Section SecID="580" OrdBy="210" Name="State of Use of the Measure">
    <Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one">
      <FieldValue Value="Current routine use" />
    </Field>
    <Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
  </Section>
  <Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use">
    <Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice">
      <FieldValue Value="Ambulatory/Office-based Care" />
    </Field>
    <Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one">
      <FieldValue Value="Clinical Practice or Public Health Sites" />
    </Field>
    <Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one">
      <FieldValue Value="Unspecified" />
    </Field>
    <Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Age 18 to 75 years&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one">
      <FieldValue Value="Either male or female" />
    </Field>
  </Section>
  <Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care">
    <Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text">
      <FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text">
      <FieldValue Value="&lt;ul&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories">
    <Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice">
      <FieldValue Value="Living with Illness" />
    </Field>
    <Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="593" OrdBy="370" Name="Data Collection for the Measure">
    <Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The time frame pertaining to data collection is the past 12 months.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one">
      <FieldValue Value="Patients associated with provider" />
    </Field>
    <Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice">
      <FieldValue Value="Clinical Condition" />
      <FieldValue Value="Encounter" />
      <FieldValue Value="Patient/Individual (Consumer) Characteristic" />
    </Field>
    <Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xA;Number of patients ages 18 to 75 years old who have type 2 diabetes mellitus (T2DM)&lt;/p&gt;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Data Collection&lt;/strong&gt;: Data should be collected from electronic medical records (EMR) for all patient visits in the past 12 months.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xA;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xA;Number of patients with any of the following:&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;1&quot;&gt;&#xA;    &lt;li&gt;Glycated hemoglobin (HgbA1c) greater than 9% &lt;/li&gt;&#xA;    &lt;li&gt;Atherosclerotic cardiovascular disease (ASCVD) and not on a statin &lt;/li&gt;&#xA;    &lt;li&gt;Established ASCVD and no documentation of daily aspirin use (unless contraindicated) &lt;/li&gt;&#xA;    &lt;li&gt;Blood pressure measurement greater than 160/100 mmHg &lt;/li&gt;&#xA;    &lt;li&gt;Currently smoke &lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xA;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one">
      <FieldValue Value="Fixed time period or point in time" />
    </Field>
    <Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many">
      <FieldValue Value="Electronic health/medical record" />
    </Field>
    <Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one">
      <FieldValue Value="Physiologic Health State (Intermediate Outcome)" />
    </Field>
    <Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="605" OrdBy="490" Name="Computation of the Measure">
    <Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one">
      <FieldValue Value="Measure is disaggregated into categories based on different definitions of the denominator and/or numerator" />
    </Field>
    <Field FieldID="3509" OrdBy="510" ID="607" Name="Basis for Disaggregation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is disaggregated based on different definitions of the numerator.&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot; start=&quot;1&quot;&gt;&#xA;    &lt;li&gt;Number of patients with glycated hemoglobin (HgbA1c) greater than 9% &lt;/li&gt;&#xA;    &lt;li&gt;Number of patients with atherosclerotic cardiovascular disease (ASCVD) and not on a statin &lt;/li&gt;&#xA;    &lt;li&gt;Number of patients with established ASCVD and no documentation of daily aspirin use (unless contraindicated) &lt;/li&gt;&#xA;    &lt;li&gt;Number of patients with blood pressure measurement greater than 160/100 mmHg &lt;/li&gt;&#xA;    &lt;li&gt;Number of patients who currently smoke &lt;/li&gt;&#xA;    &lt;li&gt;Number of patients with any of the above &lt;/li&gt;&#xA;&lt;/ol&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many">
      <FieldValue Value="Composite/Scale" />
      <FieldValue Value="Rate/Proportion" />
    </Field>
    <Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one">
      <FieldValue Value="Desired value is a lower score" />
    </Field>
    <Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
    <Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3">
      <FieldValue Value="not defined yet" />
    </Field>
  </Section>
  <Section SecID="615" OrdBy="590" Name="Identifying Information">
    <Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Management of T2DM in high-risk patients.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text">
      <FieldValue Value="Diagnosis and Management of Type 2 Diabetes Mellitus in Adults" />
    </Field>
    <Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist">
      <FieldValue Value="Institute for Clinical Systems Improvement - Nonprofit Organization" />
    </Field>
    <Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p">
      <FieldValue Value="Institute for Clinical Systems Improvement - Nonprofit Organization" />
    </Field>
    <Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Institute for Clinical Systems Improvement's (ICSI's) work is funded by the annual dues of the member medical groups and five sponsoring health plans in Minnesota and Wisconsin.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Work Group Members&lt;/em&gt;: Bruce Redmon, MD (&lt;em&gt;Work Group Leader&lt;/em&gt;) (University of Minnesota) (Endocrinology); David Caccamo, MD (HealthPartners Medical Group and Regions Hospital) (Family Medicine); Ryan Michels, PharmD, BCPS (HealthPartners Medical Group and Regions Hospital) (Pharmacy); Patrick O'Connor, MD (HealthPartners Medical Group and Regions Hospital) (Family Medicine); Julie Roberts, MS, RD, CDE (HealthPartners Medical Group and Regions Hospital) (Health Education); JoAnn Sperl-Hillen, MD (HealthPartners Medical Group and Regions Hospital) (Internal Medicine); Steve Smith, MD (Mayo Clinic) (Endocrinology); Penny Louise Flavin, DNP, RN, CNP (Olmsted Medical Center) (Family Practice); Cassie Myers (Institute for Clinical Systems Improvement [ICSI]) (Project Manager); Linda Setterlund, MA, CPHQ (ICSI) (Clinical Systems Improvement Facilitator)&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Institute for Clinical Systems Improvement (ICSI) has long had a policy of transparency in declaring potential conflicting and competing interests of all individuals who participate in the development, revision and approval of ICSI guidelines and protocols. &lt;/p&gt;&#xA;&lt;p&gt;In 2010, the ICSI Conflict of Interest Review Committee was established by the Board of Directors to review all disclosures and make recommendations to the board when steps should be taken to mitigate potential conflicts of interest, including recommendations regarding removal of work group members. This committee has adopted the Institute of Medicine Conflict of Interest standards as outlined in the report Clinical Practice Guidelines We Can Trust (2011). &lt;/p&gt;&#xA;&lt;p&gt;Where there are work group members with identified potential conflicts, these are disclosed and discussed at the initial work group meeting. These members are expected to recuse themselves from related discussions or authorship of related recommendations, as directed by the Conflict of Interest committee or requested by the work group.&lt;/p&gt;&#xA;&lt;p&gt;The complete ICSI policy regarding Conflicts of Interest is available at the &lt;a href=&quot;https://www.icsi.org/_asset/fwsfmi/coi_policyletter.pdf&quot; title=&quot;ICSI Web site&quot;&gt;ICSI Web site&lt;/a&gt;. &lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Disclosure of Potential Conflicts of Interest&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;David Caccamo, MD (Work Group Member) &lt;/strong&gt;&lt;br /&gt;&#xA;Family Physician, Family Medicine, HealthPartners Medical Group and Regions Hospital &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: None &lt;br /&gt;&#xA;Research Grants: None &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Penny Louise Flavin, DNP, RN, CNP (Work Group Member) &lt;/strong&gt;&lt;br /&gt;&#xA;Family Practice, Olmsted Medical Center &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: None &lt;br /&gt;&#xA;Research Grants: None &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Ryan Michels, PharmD, BCPS (Work Group Member)&lt;/strong&gt; &lt;br /&gt;&#xA;Clinical Pharmacist, HealthPartners Medical Group and Regions Hospital &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: None &lt;br /&gt;&#xA;Research Grants: None &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Patrick O'Connor, MD (Work Group Member)&lt;/strong&gt; &lt;br /&gt;&#xA;Family Medicine/Geriatrics, Senior Clinical Investigator, HealthPartners Medical Group and Regions Hospital &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: Lipid Management in Adults, Diagnosis and Treatment of Hypertension&lt;br /&gt;&#xA;Research Grants: Received institutional payment for research grants from NIH (National Institutes of Health), AHRQ (Agency for Healthcare Research and Quality, NIMH (National Institute of Mental Health), NHLBI (National Heart, Lung and Blood Institute) and to develop standards of diabetes care for American Diabetes Association &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Bruce Redmon, MD (Work Group Member)&lt;/strong&gt; &lt;br /&gt;&#xA;Endocrinology, Professor, University of Minnesota Medical School &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: None &lt;br /&gt;&#xA;Research Grants: NIH (National Institutes of Health) related to ongoing diabetes clinical trial, including the Look Ahead study and GRADE study &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: Consults for the University of Minnesota and Optum Insight and is paid directly to the physician's employer&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Julie Roberts, MS, RD, CDE (Work Group Member) &lt;/strong&gt;&lt;br /&gt;&#xA;Registered Dietician, HealthPartners Medical Group and Regions Hospital &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: None &lt;br /&gt;&#xA;Research Grants: None &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None &lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Steve Smith, MD (Work Group Member)&lt;/strong&gt; &lt;br /&gt;&#xA;Endocrinology, Consultant, Medical Director of Patient Education, Mayo Clinic &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: None &lt;br /&gt;&#xA;Research Grants: None &lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;JoAnn Sperl-Hillen, MD (Work Group Member)&lt;/strong&gt; &lt;br /&gt;&#xA;Internal Medicine, Investigator, HealthPartners Medical Group and Regions Hospital &lt;br /&gt;&#xA;National, Regional, Local Committee Affiliations: None &lt;br /&gt;&#xA;Guideline Related Activities: Has served on guideline group for BMJ Online T2DM guideline &lt;br /&gt;&#xA;Research Grants: Receives programmatic support paid to her institution for the following: Stimulated Diabetes Training for Resident Physicians (NIDDK funded), Primary investigator; Personalized Physician Learning for HTN (NHLBI), co-investigator; Priorities (NHLBI), co-investigator; Hyperlink (NHLBI), co-investigator; travel and expenses paid for by an educational grant from Sanofi through the International Diabetes Center&lt;br /&gt;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date">
      <FieldValue Value="2014 Jul" />
    </Field>
    <Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Scientific documents are revised every 12 to 24 months as indicated by changes in clinical practice and literature.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The next scheduled revision will occur within 24 months.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the measure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The measure developer reaffirmed the currency of this measure in January 2016.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Source available for purchase from the &lt;a href=&quot;https://www.icsi.org/guidelines__more/purchase_guidelines/&quot; title=&quot;ICSI Web site&quot;&gt;Institute for Clinical Systems Improvement (ICSI) Web site&lt;/a&gt;. Also available to ICSI members for free at the &lt;a href=&quot;https://www.icsi.org/guidelines__more/member_access/&quot; title=&quot;ICSI Web site&quot;&gt;ICSI Web site&lt;/a&gt; and to Minnesota health care organizations free by request at the &lt;a href=&quot;https://www.icsi.org/guidelines__more/minnesota_nonmember_access/&quot; title=&quot;ICSI Web site&quot;&gt;ICSI Web site&lt;/a&gt;. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;For more information, contact ICSI at 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; Phone: 952-814-7060; Fax: 952-858-9675; Web site: &lt;a href=&quot;http://www.icsi.org&quot; title=&quot;ICSI Web site&quot;&gt;www.icsi.org&lt;/a&gt;; E-mail: &lt;a href=&quot;mailto:icsi.info@icsi.org&quot;&gt;icsi.info@icsi.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary was completed by ECRI Institute on January 5, 2015.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The information was reaffirmed by the measure developer on January 13, 2016.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures. &lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="641" OrdBy="850" Name="Production">
    <Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Redmon B, Caccamo D, Flavin P, Michels R, O'Connor P, Roberts J, Smith S, Sperl-Hillen J. Diagnosis and management of type 2 diabetes mellitus in adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2014 Jul. 85 p.  [197 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NQMC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>